Wolfgang Osterrieder

Author

Roche (Switzerland)

Also Known As

W Osterrieder, W. OSTERRIEDER, W. Osterrieder, Wolfgang Osterrieder

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)Saarland University Heidelberg University

About

Wolfgang Osterrieder is an author at Roche (Switzerland) specializing in medicine, physiology, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	23	1.8K
2	Social Sciences	5	5	198
3	Public Health	2	2	122
4	Engineering	1	1	23
5	Natural Sciences	1	1	93

Wolfgang Osterrieder

Publications

Citations

H-Index

Page 1

	Year	Citations
Injection of subunits of cyclic AMP-dependent protein kinase into cardiac myocytes modulates Ca2+ current Wolfgang Osterrieder, Gustavo Brum, J. Hescheler, Nature Cardiac MuscleSignal TransductionMolecular PhysiologyCell SignalingPhysiology	1982	416
?-Adrenergic increase in the calcium conductance of cardiac myocytes studied with the patch clamp Gustavo Brum, Wolfgang Osterrieder, W. Trautwein Pflügers Archiv - European Journal of Physiology Cardiac MusclePatch ClampPhysiology-Adrenergic IncreaseElectrophysiology	1984	205
Injection of catalytic subunit of cAMP-dependent protein kinase into isolated cardiac myocytes Gustavo Brum, Veit Flockerzi, Franz Hofmann, Pflügers Archiv - European Journal of Physiology Cell PhysiologyCardiac MuscleCardiomyopathyMolecular PhysiologySignal Transduction	1983	150
Role of angiotensin II in injury-induced neointima formation in rats. Wolfgang Osterrieder, Rita Müller, Jerry S. Powell, Hypertension HypertensionVascular DiseaseRenal InflammationPharmacotherapyAng Ii	1991	116
In Vitro Pharmacologic Profile of Ro 40-5967, a Novel Ca2+ Channel Blocker with Potent Vasodilator but Weak Inotropic Action Wolfgang Osterrieder, Mark Holck Journal of Cardiovascular Pharmacology	1989	101
Ro 40–5967: A New Nondihydropyridine Calcium Antagonist Jean‐Paul Clozel, Wolfgang Osterrieder, Cornells H. Kleinbloesem, Cardiovascular Drug Reviews Molecular PharmacologyPharmaceutical ScienceMedicinePharmacological AgentPharmacotherapy	1991	98
Ro 15-4513: Partial inverse agonism at the BZR and interaction with ethanol E. P. Bonetti, Willy P. Burkard, M. Gabl, Pharmacology Biochemistry and Behavior Partial Inverse AgonismNatural SciencesMolecular BiologyComputational ChemistryQuantum Chemistry	1988	93
In Vitro Pharmacologic Profile of Ro 40-5967, a Novel Ca2+ Channel Blocker with Potent Vasodilator but Weak Inotropic Action Wolfgang Osterrieder, Mark Holck Journal of Cardiovascular Pharmacology Cardiovascular PharmacologyPotent VasodilatorVitro Pharmacologic ProfilePharmacotherapyCardiovascular Function	1989	90
The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts Jean‐Paul Clozel, Murielle M. Véniant, Wolfgang Osterrieder Cardiovascular Drugs and Therapy Molecular PharmacologyCardiomyopathyHeart FailureMolecular PhysiologyCardiac Muscle	1990	82
On the kinetics of the potassium channel activated by acetylcholine in the S-A node of the rabbit heart Wolfgang Osterrieder, Akinori Noma, W. Trautwein Pflügers Archiv - European Journal of Physiology Cardiac MuscleCardiac MechanicNeurophysiologyMedicinePhysiology	1980	81

Page 1